Authors:
Dowlati, A
Hoppel, CL
Ingalls, ST
Majka, S
Li, XL
Sedransk, N
Spiro, T
Gerson, SL
Ivy, P
Remick, SC
Citation: A. Dowlati et al., Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days, J CL ONCOL, 19(8), 2001, pp. 2309-2318
Authors:
Dowlati, A
Levitan, N
Gordon, NH
Hoppel, CL
Gosky, DM
Remick, SC
Ingalls, ST
Berger, SJ
Berger, NA
Citation: A. Dowlati et al., Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer, CANC CHEMOT, 47(2), 2001, pp. 141-148
Authors:
Rose, PG
Gordon, NH
Fusco, N
Fluellen, L
Rodriguez, M
Ingalls, ST
Hoppel, CL
Citation: Pg. Rose et al., A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma, GYNECOL ONC, 78(2), 2000, pp. 228-234
Authors:
Spiro, TP
Gerson, SL
Liu, LL
Majka, S
Haaga, J
Hoppel, CL
Ingalls, ST
Pluda, JM
Willson, JKV
Citation: Tp. Spiro et al., O-6-benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directrd DNA repair, CANCER RES, 59(10), 1999, pp. 2402-2410